NCI seeks suramin research partner
Executive Summary
National Cancer Institute announces opportunity for a Cooperative Research and Development Agreement (CRADA) for clinical development of its anti-cancer compound suramin. NCI says the drug appears effective in treating several types of cancers in pre-clinical studies. A study reported in the Jan. 1 Journal of the National Cancer Institute by University of Maryland researchers states that prolonged administration of suramin over at least three months "was associated with major antitumor activity" in patients with prostate cancer. Of 26 evaluable patients, 14 have shown a 50% or greater decrease. Information may be obtained from Dale Shoemaker, Executive Secretary, CRADA Selection Committee, 301/496-7912.